News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cognition Therapeutics, Inc. - Common Stock
(NQ:
CGTX
)
1.465
+0.085 (+6.16%)
Streaming Delayed Price
Updated: 11:30 AM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cognition Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
January 06, 2026
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
December 03, 2025
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 01, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease
November 13, 2025
Study conducted in collaboration with the Alzheimer’s Clinical Trials Consortium
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
November 06, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Here are the top movers in Monday's session.
↗
September 15, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 15, 2025
Via
Benzinga
Which stocks are moving on Monday?
↗
September 15, 2025
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025
↗
September 03, 2025
Almost all of it was event-driven, while the bulk of these gains were made by small biopharma names.
Via
The Motley Fool
Topics
Intellectual Property
Stocks
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
September 02, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Wondering what's happening in today's pre-market session?
↗
August 28, 2025
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
August 28, 2025
Via
Benzinga
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
↗
August 28, 2025
Via
Benzinga
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
August 27, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 26, 2025
Via
Benzinga
The market is filled with gapping stocks in Monday's session.
↗
August 25, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via
Chartmill
What's going on in today's session
↗
August 22, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
August 22, 2025
Via
Benzinga
Friday's session: top gainers and losers
↗
August 22, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 14, 2025
Via
Benzinga
Thursday's session: top gainers and losers
↗
August 14, 2025
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Wednesday's session: gap up and gap down stocks
↗
August 13, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
What's going on in today's pre-market session
↗
August 13, 2025
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 13, 2025
Via
Benzinga
Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
↗
August 13, 2025
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an...
Via
Benzinga
Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug
↗
August 13, 2025
Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 12, 2025
Via
Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
↗
August 12, 2025
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
August 12, 2025
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition (CGTX) Q2 Grant Income Jumps
↗
August 08, 2025
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Close
